FIELD: medicine.
SUBSTANCE: pharmaceutical composition contains a therapeutic amount of a sterile isolated chemotactic stem cell product, a stabilising amount of serum and a therapeutic agent for promoting the existing cardiomyocyte function in order to compensate the deprivation of the cardiomyocyte function caused by the cardiomyocyte death.
EFFECT: reducing the number of injuries at the infarction due to preventing the cardiomyocyte loss following the acute myocardial infarction by improving perfusion and preventing apoptosis.
27 cl, 13 ex, 4 dwg, 36 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS IMPROVING INFARCTION PERFUSION, AND METHODS FOR RECOVERING VASCULAR INVOLVEMENT | 2009 |
|
RU2497532C2 |
| CELL-BASED THERAPY OF ISCHEMIC TISSUE | 2009 |
|
RU2535966C2 |
| DEVICES AND METHODS FOR SELECTION OF CELLS RESISTANT TO APOPTOTIC SIGNALS AND THEIR APPLICATIONS | 2013 |
|
RU2630301C2 |
| METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS | 2019 |
|
RU2824194C2 |
| GENE THERAPY IN PATIENTS WITH FANCONI ANEMIA | 2017 |
|
RU2801241C2 |
| METHODS AND COMPOSITIONS FOR STEM CELL TRANSPLANTATION | 2016 |
|
RU2757818C2 |
| PURIFIED CYANOBACTERIAE COMPONENT AND METHOD OF APPLICATION | 2006 |
|
RU2417093C2 |
| STROKE TREATMENT WITH APPLICATION OF ISOLATED PLACENTAL CELLS | 2009 |
|
RU2558778C2 |
| METHODS AND APPLICATION OF TISSUE CULTURE SYSTEMS EX VIVO | 2012 |
|
RU2631807C2 |
| COMPOSITIONS AND METHODS OF STEM CELL TRANSPLANTATION | 2019 |
|
RU2809803C2 |
